NovoPath’s AP LIS Receives Frost & Sullivan Technology Leadership Award for its Advanced Features that Transform AP Laboratory Workflow
June 05, 2018 at 8:00 AM
NovoPath’s AP LIS Receives Frost & Sullivan Technology Leadership Award for its Advanced Features
that Transform AP Laboratory Workflow
NovoPath's modules offer robust functionality using the latest industry techniques to boost
productivity and enable material cost savings for labs aiming for a higher grade of operations
SANTA CLARA, Calif. — June 5, 2018 — Based on its recent analysis of the North American market for
anatomic pathology laboratory information systems (AP LIS), Frost & Sullivan recognizes NovoPath,
Inc. with the 2018 North American Enabling Technology Leadership Award. Over the last two decades,
NovoPath’s LIS software for AP, simply called NovoPath™, has consistently garnered high ratings
from clients for its continual improvement and functional expansion, as well as its ease of use.
NovoPath™ offers an array of modules inspired by client needs and a strong understanding of
technology and market trends. These modules increase productivity and efficiency by streamlining
workflow, promoting superior diagnostic outcomes, and providing lab managers a real-time view into
NovoPathTM clients benefit from several value-enhancing modules and features, including the
• Lean Process Improvement module tracks specimens from entry to storage, as well as day-to-day
activities, and highlights potential areas of improvement in patient safety, staff productivity,
quality control, and overall lab efficiency using powerful data analytics.
• Digital Pathology Readiness ensures that lab managers and pathologists have a seamless and
elegant way to view and capture relevant information from digitized slides, improving turnaround
time in the lab and allowing for remote diagnosis.
• Auto Case Distribution and Staff Scheduler dynamically distributes caseloads amongst
pathologists during the workday while keeping track of workload, availability, and other variables.
Staff Scheduler saves significant time for labs that manually assign caseload.
• NovoNotifier™ is a patient report delivery system that delivers patient reports to mobile
devices and downloads and prints reports at a client’s site automatically upon release. This
eliminates human intervention and delivers fast and reliable patient results.
These modules and features integrate fully as part of a powerful LIS that includes functionalities
expected in more expensive systems, such as personalized results for clients, electronic sign off
and data exchange, a wide range of interfaces to other systems and instruments, voice dictation and
recognition, and several methods of reporting results.
"NovoPath™ is used to diagnose over 4 million new specimens each year and has a customer base of
more than 309 sites. This software platform has experienced consistent growth due to its
usefulness, broad functionality, and customizable features," said Supratik Paul, senior industry
analyst. "Besides, it is cost effective, offers outstanding process optimization due to on-time
delivery, and is simpler to use than competing solutions."
NovoPath™ has found eager acceptance in customer segments ranging from specialized reference
laboratories to large general hospitals. The company enjoys a huge competitive advantage in a
market where clients desire customized LIS owing to constantly changing regulations and payment cap
revisions. In addition to NovoPath’s success in the United States, the company has experienced
growth in international markets as well.
NovoPath™ has leveraged its brand to sign several strategic partnerships with leading healthcare
and IT solutions providers, as well as software developers. For example, its partnership with
Allscripts (formerly McKesson), a leading healthcare services and IT provider, has allowed
Allscripts to present an integrated LIS solution to its customer base. Similarly, NovoPath worked
with Philips IntelliSite Pathology Solution to develop an integrated digital imaging platform for
viewing pathology slides, improving turn-around-time for labs, and offering actionable information.
"Overall, Frost & Sullivan believes that NovoPath’s strategic partnerships with top healthcare
service providers, modern technology, and solid brand equity in the AP ecosystem have positioned it
as the AP LIS vendor of choice in the North American market," noted Supratik Paul .
Each year, Frost & Sullivan presents this award to a company that has developed a pioneering
technology that not only enhances current products, but also enables the development of new
products and applications. The award recognizes the high market acceptance potential of the
Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global
markets for demonstrating outstanding achievement and superior performance in areas such as
leadership, technological innovation, customer service, and strategic product development. Industry
analysts compare market participants and measure performance through in-depth interviews, analysis,
and extensive secondary research to identify best practices in the industry.
NovoPath, Inc. is a leading U.S.-based Lab Information Systems (LIS) company with over 24 years of
experience in serving the Anatomic, Clinical and Molecular Pathology, Genetic Testing and Clinical
Trials marketplaces. NovoPath's clients range from national and regional reference labs to
Teaching Hospitals, Regional and Community Hospitals and Specialty Labs. NovoPath's mission is to
provide unique and unparalleled solutions and services to all aspects of the Diagnostic Laboratory
sector in a way that improves workflow, reduces the probability of human error, ensures results
accuracy for greater patient safety, protects patient confidentiality, and above all, produces more
precise and informative diagnostic outcomes.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage
visionary innovation that addresses the global challenges and related growth opportunities that
will make or break today's market participants. For more than 50 years, we have been developing
growth strategies for the global 1000, emerging businesses, the public sector and the investment
community. Contact us: Start the discussion.
Samantha Park P: 210.247.2426